New product development – New products are the foundation of our future. We are working toward having more than 50 percent of our sales come from products introduced within the last three years. This is important because it's a good benchmark to let us know that we are continuing to meet the changing needs of our customers.

The businesses that now comprise Magellan have a strong track record of working closely with customers to identify, develop, and ultimately deliver what customers actually need today – and tomorrow. We use a platform-development approach to product development so we can share advances that we make in one area across a number of different product groups. This not only helps save precious resources, but also ensures product compatibility and helps speed products to market.

In 2004, we introduced several groundbreaking new products, including ESA's Plasma Metanephrine kit, cleared by the FDA for measuring cancer markers in plasma, and the Corona^® Charged Aerosol Detector (CAD^®), a breakthrough, universal detector technology for HPLC (High Performance Liquid Chromatography). In March 2005, the Corona was honored with the Silver PITTCON Editors' Award for best new product at PITTCON 2005 – the premier U.S. exhibition and conference of analytical instruments. Click here to learn more about how the Corona is able to meet market needs never before addressable with traditional detection technologies.

In 2006, Dynex launched the DS2 automated immunoassay workstation for low-throughput labs, a two-plate version of its successful DSX system, which performs all the steps required for immunoassays (adding reagents, washing, incubation, and optical detection). ESA unveiled the next generation of its successful point-of-care device for measuring lead levels in blood – LeadCare II – the world’s only CLIA-waived blood-lead-testing system. TREK Diagnostics continues to innovate with important additions to its VersaTREK^® mycobacteria detection & susceptibility testing and Sensititre^® platforms.